two key u.s. congressional committee members friday call investigation whether mylan nv fire raise price epipen device overcharge government low-income healthcare program allergy treatment letter secretary department health human service senator ron wyden representative frank pallone democrats seek clarification whether epipen classify generic non-innovator drug brand-name drug medicaid program current law brand drug generic drug available single source require pay rebate amount least 23.1 percent average manufacturer price generic drug subject much low 13 percent rebate mylan email statement say comply laws regulations regard medicaid rebate intend file regulators next april require new guidelines epipen classify non-innovator product device jab dose drug epinephrine thigh counter dangerous allergic reactions peanuts food allergies bee sting mylan whose tax address netherlands corporate headquarter canonsburg pennsylvania raise u.s. price epipen less 100 acquire product 2007 600 amid outcry parent consumer group u.s. politicians company say monday soon launch first generic version device 300 half list price brand product wyden rank member senate finance committee pallone rank member house energy commerce committee say letter friday recently come attention mylan classify epipen generic drug medicaid rebate program even though consider new drug food drug administration share mylan fell 4.7 percent close 39.97 friday drop 19 percent since mid-august u.s. lawmakers question mylan 's medicaid epipen rebate